BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karanu F, Ott L, Webster DA, Stehno-Bittel L. Improved harmonization of critical characterization assays across cell therapies. Regen Med 2020;15:1661-78. [PMID: 32589107 DOI: 10.2217/rme-2020-0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Tan MI, Alfarafisa NM, Septiani P, Barlian A, Firmansyah M, Faizal A, Melani L, Nugrahapraja H. Potential Cell-Based and Cell-Free Therapy for Patients with COVID-19. Cells 2022;11:2319. [DOI: 10.3390/cells11152319] [Reference Citation Analysis]
2 Tan LS, Chen JT, Lim LY, Teo AKK. Manufacturing clinical-grade human induced pluripotent stem cell-derived beta cells for diabetes treatment. Cell Prolif 2022;:e13232. [PMID: 35474596 DOI: 10.1111/cpr.13232] [Reference Citation Analysis]
3 Vladimira R, Ines B. Role of flow cytometry in evaluation of the cellular therapy products used in haematopoietic stem cell transplantation. Int J Lab Hematol 2022. [PMID: 35419954 DOI: 10.1111/ijlh.13849] [Reference Citation Analysis]
4 Abdel-Azim H, Dave H, Jordan K, Rawlings-Rhea S, Luong A, Wilson AL. Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy. Cytotherapy 2021:S1465-3249(21)00783-0. [PMID: 34711500 DOI: 10.1016/j.jcyt.2021.08.007] [Reference Citation Analysis]
5 Yamada S, Behfar A, Terzic A. Regenerative medicine clinical readiness. Regen Med 2021;16:309-22. [PMID: 33622049 DOI: 10.2217/rme-2020-0178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]